標(biāo)題: Titlebook: Development of Innovative Drugs via Modeling with MATLAB; A Practical Guide Ronald Gieschke,Daniel Serafin Book 2014 Springer-Verlag Berlin [打印本頁(yè)] 作者: 烹飪 時(shí)間: 2025-3-21 16:40
書目名稱Development of Innovative Drugs via Modeling with MATLAB影響因子(影響力)
書目名稱Development of Innovative Drugs via Modeling with MATLAB影響因子(影響力)學(xué)科排名
書目名稱Development of Innovative Drugs via Modeling with MATLAB網(wǎng)絡(luò)公開度
書目名稱Development of Innovative Drugs via Modeling with MATLAB網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Development of Innovative Drugs via Modeling with MATLAB被引頻次
書目名稱Development of Innovative Drugs via Modeling with MATLAB被引頻次學(xué)科排名
書目名稱Development of Innovative Drugs via Modeling with MATLAB年度引用
書目名稱Development of Innovative Drugs via Modeling with MATLAB年度引用學(xué)科排名
書目名稱Development of Innovative Drugs via Modeling with MATLAB讀者反饋
書目名稱Development of Innovative Drugs via Modeling with MATLAB讀者反饋學(xué)科排名
作者: EWER 時(shí)間: 2025-3-21 21:38 作者: 厭倦嗎你 時(shí)間: 2025-3-22 01:36
Ronald Gieschke,Daniel SerafinProvides concepts for the creation of drug-disease models.Written from the industry perspective.Based on many years of experience.Includes supplementary material: 作者: Dorsal 時(shí)間: 2025-3-22 07:00 作者: 細(xì)頸瓶 時(shí)間: 2025-3-22 09:21
Outlook,rgans (e.g., heart, liver, and brain), there are computational representations that have already proved their worth. The European Community financially supports activities in this area, such as the Drug Disease Model Resource (DDMoRe) as part of the Innovative Medicines Initiative (IMI) and the Human Brain Project.作者: Tempor 時(shí)間: 2025-3-22 15:48 作者: Tempor 時(shí)間: 2025-3-22 17:44
Berthold Heinrich,Wolfgang Schneideratients with differentiated medicines that can be afforded by health care systems is proving more and more difficult. Today’s medical treatment concepts are largely determined by drugs that act on predefined targets whereas previously a more phenomenological approach was taken. Drug development is a作者: saphenous-vein 時(shí)間: 2025-3-22 23:05 作者: 鋸齒狀 時(shí)間: 2025-3-23 02:55
Grundlagen der Motorprozessrechnungtreatments can be envisaged. Physiologic models of affected body organs or systems provide the basis for implementing disease mechanisms. The large amount of (patho)-physiologic information makes for potentially (over)elaborate physiologic/disease models. Drug-disease models combine pharmacologic mo作者: 是貪求 時(shí)間: 2025-3-23 07:49 作者: CARK 時(shí)間: 2025-3-23 13:47
Hybridantriebe und Range Extenderthis purpose, the trial is simulated many times, taking into account fixed and random effects that were assessed in a previous population analysis. Also, the impact of ad hoc assumptions regarding the population to be treated, the dosage regimen including dosage adjustment rules, and the pharmacolog作者: parsimony 時(shí)間: 2025-3-23 16:56
Günter P. Merker,Christian Schwarzrgans (e.g., heart, liver, and brain), there are computational representations that have already proved their worth. The European Community financially supports activities in this area, such as the Drug Disease Model Resource (DDMoRe) as part of the Innovative Medicines Initiative (IMI) and the Huma作者: nullify 時(shí)間: 2025-3-23 18:45 作者: 搜尋 時(shí)間: 2025-3-24 00:26 作者: 言外之意 時(shí)間: 2025-3-24 03:28
Background of Pharmacologic Modeling,atients with differentiated medicines that can be afforded by health care systems is proving more and more difficult. Today’s medical treatment concepts are largely determined by drugs that act on predefined targets whereas previously a more phenomenological approach was taken. Drug development is a作者: HAVOC 時(shí)間: 2025-3-24 07:22
First Example of a Computational Model, on palmar and plantar skin. Models for tumor growth and skin turnover are combined with pharmacokinetic (PK) and pharmacodynamic (PD) models to assess the impact of two alternative dosing regimens on efficacy and safety. Both regimens deliver the same cumulative drug amount, but one regimen employs作者: Flawless 時(shí)間: 2025-3-24 11:09
Drug-Disease Modeling,treatments can be envisaged. Physiologic models of affected body organs or systems provide the basis for implementing disease mechanisms. The large amount of (patho)-physiologic information makes for potentially (over)elaborate physiologic/disease models. Drug-disease models combine pharmacologic mo作者: Intellectual 時(shí)間: 2025-3-24 15:38 作者: 策略 時(shí)間: 2025-3-24 22:56 作者: Friction 時(shí)間: 2025-3-25 02:10
Outlook,rgans (e.g., heart, liver, and brain), there are computational representations that have already proved their worth. The European Community financially supports activities in this area, such as the Drug Disease Model Resource (DDMoRe) as part of the Innovative Medicines Initiative (IMI) and the Huma作者: FIR 時(shí)間: 2025-3-25 06:58
Book 2014s to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropriate dosage regimens? .Written from the industry perspective and based on many years of experience, this book offers:.- Concepts for creation of drug-disease models, introdu作者: 痛打 時(shí)間: 2025-3-25 10:50 作者: PAD416 時(shí)間: 2025-3-25 14:58
Population Analyses,the 1970s and have been continuously refined thereafter. Parameters can now be estimated using stochastic algorithms that avoid previous likelihood approximations. The search for covariates became automated and model diagnostic procedures much more extended, as exemplified by visual predictive checks.作者: GRACE 時(shí)間: 2025-3-25 19:10
upplementary material: .The development of innovative drugs is becoming more difficult while relying on empirical approaches. This inspired all major pharmaceutical companies to pursue alternative model-based paradigms. The key question is: How to find innovative compounds and, subsequently, appropr作者: NATTY 時(shí)間: 2025-3-25 20:41 作者: 天文臺(tái) 時(shí)間: 2025-3-26 02:21 作者: 不透明性 時(shí)間: 2025-3-26 05:25
Berthold Heinrich,Wolfgang Schneidertreatment concept into a marketable drug, industry specialists increasingly advocate the consistent application of mathematical modeling based on realistic models of pharmacokinetics, pharmacodynamics, and disease biology.作者: Ornithologist 時(shí)間: 2025-3-26 10:07
Grundlagen der Motorprozessrechnungof a disease, disease progression models will mainly be built empirically. Drug-disease models help to identify and assess appropriate targets at an early state of drug development, as well as the planning of trials in later stages of development.作者: TRACE 時(shí)間: 2025-3-26 14:39
Background of Pharmacologic Modeling,treatment concept into a marketable drug, industry specialists increasingly advocate the consistent application of mathematical modeling based on realistic models of pharmacokinetics, pharmacodynamics, and disease biology.作者: 數(shù)量 時(shí)間: 2025-3-26 19:51
Drug-Disease Modeling,of a disease, disease progression models will mainly be built empirically. Drug-disease models help to identify and assess appropriate targets at an early state of drug development, as well as the planning of trials in later stages of development.作者: 厚顏無恥 時(shí)間: 2025-3-27 00:41 作者: 脆弱吧 時(shí)間: 2025-3-27 03:00
Hybridantriebe und Range Extendery of the drug, etc., can be tested. Clinical trial simulation is applicable at all stages of drug development. Essentially, it is a forecast based on current knowledge codified by a PK-PD/disease model.作者: Genome 時(shí)間: 2025-3-27 07:38
est in life sciences and skills in a high-level programming language such as MATLAB, are encouraged to engage in model-based pharmaceutical research and development..978-3-662-52110-6978-3-642-39765-3作者: 即席演說 時(shí)間: 2025-3-27 11:07
Development of Innovative Drugs via Modeling with MATLABA Practical Guide作者: 文藝 時(shí)間: 2025-3-27 15:23 作者: 可用 時(shí)間: 2025-3-27 18:06 作者: 使服水土 時(shí)間: 2025-3-27 22:21
Isaac John,Santhakumar Mohan,Philippe Wengerrs (e.g., growth factors) and their receptors are often encoded by a class of genes called proto-oncogenes. Cells also contain several inhibitory proteins, encoded by tumor suppressor genes which act as either censors or pacers (Marx, 1994).作者: badinage 時(shí)間: 2025-3-28 04:35
,Well-Orders Realized by?C.E. Equivalence Relations,n this paper, we obtain a complete characterization of well-orders . realizable by a given ceer . for the case when . realizes some ordinal .. Informally speaking, our proofs develop methods of fine-tuning the behavior of limit points of . via computability-theoretic properties of ..作者: 植物學(xué) 時(shí)間: 2025-3-28 07:44
